1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Vicore Pharma Holding AB

Vicore Pharma Holding AB

VCRE
Vicore Pharma Holding ABUS flagNASDAQ
11.59
USD
+0.04
- -
3.26BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.9
0.58
0.59
0.53
0.22
- -
- -
- -
- -
- -
7.99
0.16
0.11
Basic EPS, GAAP
-1.2
14.4
-3.16
-4.61
-13.88
-9.22
-21.04
-26.34
-41.4
-38.86
-32.2
-12.32
-19.9
-14.35
Free Cash Flow per Basic Share
- -
-12.96
-3.22
-5.78
-16
-14.9
-19.7
-22.05
-37.03
-40.81
-25.85
-12.05
-15.66
-12.14
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.01
4.04
5.66
2.18
3.1
8.43
6.24
5.71
5.2
3.44
3.97
4.81
3.89
3.52
Tangible Book Value per Share
0.93
1.25
2.71
1.03
2.2
6.38
4.92
4.57
4.28
2.63
3.95
4.81
3.89
3.52
Basic Weighted Avg Shares
1
1
1
1
2
2
4
6
7
7
10
14
24
25
Sales/Revenue/Turnover
- -
1
1
1
1
1
- -
- -
- -
- -
- -
109
4
3
Operating Margin (%)
- -
-583.31
-540.83
-780.4
-3,022.85
-8,186.22
- -
- -
- -
- -
- -
-174.09
-11,905.82
-13,325.73
Depreciation Expense
- -
- -
- -
- -
- -
- -
1
4
4
4
3
2
- -
- -
Net Income, GAAP
-2
14
-5
-7
-24
-22
-93
-147
-296
-288
-311
-169
-477
-361
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
1,608.34
-544.05
-780.75
-2,599.89
-4,267.91
- -
- -
- -
- -
- -
-154.22
-12,509.14
-13,049.58
Working Capital
13
-2
21
1
20
213
250
280
312
223
455
1,130
1,098
990
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
40
54
82
32
58
285
322
355
383
289
455
1,129
1,095
991
Return on Invested Capital (%)
- -
-10.41
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
28.97
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
29.21
-6.74
-11.72
-54.36
-12.64
-30.67
-43.44
-80.37
-85.79
-83.53
-21.28
-42.92
-35.91

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
235
282
282
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
1,217
1,074
Cash, Cash Equivalents & STI
- -
1,167
1,060
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
118
85
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
62.56%
37.21%
-3%
Free Cash Flow
73.57%
41.24%
127.79%
Net Income, GAAP
93.07%
48.87%
183.14%
Sales/Revenue/Turnover
- -
- -
-96.51%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
104
- -
- -
5
109
2025
1
2
- -
- -
4
2026
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.84
-5.04
-5.37
-4.05
-12.32
2025
-4.75
-4.92
- -
-5.36
-19.9
2026
-3.86
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ahmed Mousa
Full Time Employees
37
Sector
Healthcare
Industry
Biotechnology
Address
Kornhamnstorg 53 Stockholm AB Sweden 111 27
IPO Date
Jul 2, 2026
CIK
0002124403
Website
vicorepharma.com
Similar Companies
Awakn Life Sciences Corp. (AWKNF)
Entrada Therapeutics, Inc. (TRDA)
Anhui Huaheng Biotechnology Co., Ltd. (688639.SS)
Idorsia Ltd (IDRSF)
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS)
Avalo Therapeutics, Inc. (AVTX)
Business
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing disease-modifying therapies for respiratory diseases, with an emphasis on the angiotensin II type 2 receptor (AT2) pathway. The company advances Buloxibutid (C21), an orally available small-molecule AT2 receptor agonist, in Phase II clinical development for idiopathic pulmonary fibrosis (IPF) and in early-phase trials for pulmonary arterial hypertension, while pursuing a portfolio of AT2-targeted programs. Vicore also develops Almee, an investigational medical device addressing the psychological impact of living with pulmonary fibrosis, currently in clinical development. The company operates through collaborations and development agreements with Emeriti Bio AB, HaLaCore Pharma AB to generate follow-on AT2-based compounds, and with Alex Therapeutics AB to develop a digital app supporting interstitial lung diseases, including IPF. Vicore originated as Mintage Scientific AB and is headquartered in Stockholm, Sweden, with research and development activities centered in Sweden and an international focus on respiratory disease therapeutics. The company’s business model centers on clinical-stage drug development, strategic partnerships, and platform expansion around AT2 receptor biology to address high-need pulmonary diseases in global markets. Vicore reports ongoing collaboration-driven progress, potential IP generation, and regulatory-oriented milestones as it advances its IP portfolio and associated medical devices in its pursuit of life-changing treatments for IPF and related conditions. Vicore’s primary geographic footprint includes Sweden, with development and operational activities pursued in Europe and potentially other regions through partnerships, licensing, and future commercialization efforts. The company maintains a focus on specialty biotechnology within the healthcare sector, pursuing growth through advancing clinical programs, strategic alliances, and expanded therapeutic modalities targeting the AT2 receptor pathway.

Company News

Company News APIChatGPT

  • accessnewswire.com

    Vicore Pharma to Participate in Upcoming Healthcare Conferences

  • accessnewswire.com

    Vicore Pharma to Present at the European Respiratory Society Congress 2026